IP Library Granted Patent US 7,306,917
Granted Patent B2
US 7,306,917 · App. 11/222,565 · Granted Dec 11, 2007

Cleavage of nucleic acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,306,917
App. No.
11/222,565
Granted
Dec 11, 2007
Kind
B2
Abstract

The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. The structure-specific nuclease activity of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.

Claims (30)

1. A method for detecting the presence of a target nucleic acid molecule comprising:

a) forming a cleavage structure between a target nucleic acid, a first oligonucleotide, and a second oligonucleotide, wherein the target nucleic acid comprises a first region, a second region, and a third region, said first region downstream of and contiguous to said second region, and said second region downstream of and contiguous to said third region, wherein said first oligonucleotide comprises a 3′ portion and a 5′ portion, wherein said 3′ portion of said first oligonucleotide contains a sequence of one or more nucleotides that is completely complementary to said third region of said target nucleic acid, and wherein said 5′ portion of said first oligonucleotide contains a sequence of one or more nucleotides contiguous to said 3′ portion of said first oligonucleotide that is completely complementary to said second region of said target nucleic acid, wherein said second oligonucleotide comprises a 3′ portion and a 5′ portion, wherein said 5′ portion contains a sequence or one or more nucleotides that are completely complementary to said first region of said target nucleic acid, wherein said cleavage structure is formed when said first oligonucleotide is annealed to said third and said second region of said target nucleic acid and wherein said second oligonucleotide is annealed to said first region of said target nucleic acid such that the 3′ portion of said second oligonucleotide overlaps with the sequence of nucleotides in said 5′ portion of said first oligonucleotide annealed to said second region of said target nucleic acid;

b) cleaving said cleavage structure with a thermostable enzyme having 5′ nuclease activity and substantially lacking nucleic acid polymerase activity to generate a non-target cleavage product, and

c) detecting the cleavage of said cleavage structure to detect the presence of the target nucleic acid molecule.

2. The method of claim 1 , wherein said detecting the cleavage of cleavage structure comprises detecting said non-target cleavage product.

3. The method of claim 1 , wherein said 3′ portion of said second oligonucleotide is complementary to said second region of said target nucleic acid.

4. The method of claim 1 , wherein a 3′ terminal nucleotide of said 3′ portion of said second oligonucleotide comprises a nucleotide that is mismatched to the nucleotide at the corresponding position in said target nucleic acid.

5. The method of claim 1 , wherein said 3′ portion of said second oligonucleotide consists of a single nucleotide, said second region of said target nucleic acid consists of a single nucleotide, and wherein said 3′ portion of said second oligonucleotide is mismatched with said second region of said target nucleic acid.

6. The method of claim 3 , wherein said 3′ portion of said second oligonucleotide consists of a single nucleotide, said second region of said target nucleic acid consists of a single nucleotide, and wherein said 3′ portion of said second oligonucleotide is complementary to said second region of said target nucleic acid.

7. The method of claim 1 , wherein said a 3′ terminus of said 3′ portion of said second oligonucleotide comprises an aromatic ring structure that is not a base.

8. The method of claim 1 , wherein said detecting the cleavage of said cleavage structure comprises detection of fluorescence.

9. The method of claim 1 , wherein said detecting the cleavage of said cleavage structure comprises detection of mass.

10. The method of claim 1 , wherein the said cleavage structure is labeled with fluorophore and with a component that can suppress emission in combination with said fluorophore by fluorescence energy transfer, wherein said detecting the cleavage of said cleavage structure comprises detection of a change in fluorescence energy transfer through cleavage.

11. The method of claim 10 , wherein said component that can suppress emission in combination with said fluorophore by fluorescence energy transfer comprises a second fluorophore.

12. The method of claim 1 , wherein said detecting the cleavage of said cleavage structure comprises detection selected from the group consisting of detection of radioactivity, luminescence, phosphorescence, and fluorescence polarization.

13. The method of claim 1 , wherein said detecting the cleavage of said cleavage structure comprises detection based on the charge of non-target cleavage product.

14. The method of claim 1 , wherein said thermostable enzyme comprises an amino acid sequence, where in a portion of the amino acid sequence of said thermostable enzyme is homologous to a portion of an amino acid sequence of a thermostable DNA polymerase derived a Thermus species.

15. The method of claim 1 , wherein said thermostable enzyme is a FEN-1 nuclease.

16. The method of claim 15 , wherein said FEN-1 nuclease is from an archeabacterium.

17. The method of claim 16 , wherein said archaebacterium is Methanococcus jannaschii.

18. The method of claim 16 , wherein said archaebacterium is Pyrococcus woesei.

19. The method of claim 16 , wherein said archaebacterium is Pyrococcus furiosus.

20. The method of claim 1 , wherein said target nucleic acid is DNA.

21. The method of claim 1 wherein said target nucleic acid is synthetic nucleic acid.

22. The method of claim 21 , wherein said synthetic nucleic acid comprises amplified nucleic acid.

23. The method of claim 22 , wherein said amplified nucleic acid is generated by a polymerase chain reaction.

24. The method of claim 1 , wherein said target nucleic acid is RNA.

25. The method of claim 1 , wherein said first oligonucleotide further comprises a 5′ terminal portion that is not complementary to said target nucleic acid.

26. The method of claim 1 , wherein one or more of said first and said second oligonucleotides are generated by extension of a primer with template-dependent DNA polymerase.

27. The method of claim 1 , further comprising a third oligonucleotide complementary to a fourth region of said target nucleic acid, wherein said third region of said target nucleic acid is adjacent to and downstream of said fourth region of said target nucleic acid, and wherein said forming of said cleavage structure comprises annealing said third oligonucleotide to said fourth region of said target nucleic acid.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
MERGER Recorded Oct 23, 2015
From: THIRD WAVE AGBIO, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: GEN-PROBE INCORPORATED
Reel/Frame 036934/0796 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →